Working With the Community to Improve Patient Access to Trials, Therapies

Video

Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.

“Collaboration, collaboration, collaboration... academic centers, pharma, payers think that they all understand it, but we don't understand beyond our sphere that well and that's important because the delivery systems for selling gene therapy are significantly different than they are in conventional treatments. Decanting therapies to community centers is important, but they have to be at the same standard that we are.”

Rob Richards, the administrative director of cell therapy and transplant at University of Pennsylvania, participated in the discussion on Improving Patient Participation in clinical trials/training programs to improve patient access at the 7th Annual CAR-TCR Summit 2022, held September 19-22 in Boston, Massachusetts.

CGTLive spoke with Richards to learn more about the discussion focused on strategies for improving patients access and clinical trial participation. An important piece of the puzzle, Richards discussed, is collaboration between academics, pharmaceutical companies, and payers. He discussed how academic centers can help develop other community centers to be able to host clinical trials, boost trial participation, and improve access to gene and cell therapies. He also touched on unique challenges with clinical trials evaluating cell and gene therapies compared with trials assessing traditional drugs, including therapy delivery.

Click here to watch more coverage of the 7th Annual CAR-TCR Summit 2022.

REFERENCE
Richards R. Improving Patient Participation in clinical trials/training programs to improve patient access. Presented at: 7th Annual CAR-TCR Summit 2022, September 19-22, Boston, Massachusetts.
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.